Patents by Inventor Annemieke Geluk
Annemieke Geluk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210311029Abstract: A system and method for lateral flow assays, utilizing a test strip having at least three sections, where the second section contains multiple test lines arranged at an angle to the direction of flow, each test line configured to capture at least one conjugated rare earth particle bound to an analyte of interest, where the test strip is configured to be read in a direction perpendicular to the direction of flow.Type: ApplicationFiled: August 21, 2019Publication date: October 7, 2021Applicant: INTELLIGENT MATERIAL SOLUTIONS, INC.Inventors: Joshua E. Collins, Howard Y. Bell, Paul Corstjens, Annemieke Geluk
-
Patent number: 10253073Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: GrantFiled: April 28, 2017Date of Patent: April 9, 2019Assignee: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Reinaldus Everardus Maria Toes
-
Publication number: 20170320915Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: ApplicationFiled: April 28, 2017Publication date: November 9, 2017Applicant: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus VAN DER BURG, Tom H. M. OTTENHOFF, Annemieke GELUK, Maria Johanna Philomena SCHOENMAEKERS-WELTERS, Annemieke M. DE JONG, Rienk OFFRINGA, Cornelis Johannes Maria MELIEF, Reinaldus Everardus Maria TOES
-
Patent number: 9650423Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: GrantFiled: August 21, 2015Date of Patent: May 16, 2017Assignee: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Reinaldus Everardus Maria Toes
-
Publication number: 20150343053Abstract: Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (Myco) bacterially and/or virally infected cells or tumor cells. Peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: ApplicationFiled: August 21, 2015Publication date: December 3, 2015Applicant: ACADEMISCH ZIEKENHUIS LEIDENInventors: Sjoerd Hendrikus VAN DER BURG, Tom H. M. OTTENHOFF, Annemieke GELUK, Maria Johanna Philomena SCHOENMAEKERS-WELTERS, Annemieke M. DE JONG, Rienk OFFRINGA, Cornelis Johannes Maria MELIEF, Rene Everardus Maria TOES
-
Patent number: 9115185Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: GrantFiled: February 28, 2007Date of Patent: August 25, 2015Assignee: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhoff, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Rene Everardus Maria Toes
-
Publication number: 20070292449Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: ApplicationFiled: February 28, 2007Publication date: December 20, 2007Applicant: Academisch Ziekenhuis LeidenInventors: Sjoerd Van Der Burg, Tom Ottenhoff, Annemieke Geluk, Maria Schoenmaekers-Welters, Annemieke De Jong, Rienk Offringa, Cornelis Melief, Rene Toes
-
Patent number: 7202034Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22–45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22–35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22–35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22–35 amino acid long peptides.Type: GrantFiled: December 7, 2001Date of Patent: April 10, 2007Assignee: Academisch Ziekenhuis LeidenInventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhorf, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Cornelis Johannes Maria Melief, Rene Everardus Maria Toes
-
Publication number: 20040081658Abstract: The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides.Type: ApplicationFiled: November 12, 2003Publication date: April 29, 2004Inventors: Sjoerd Hendrikus Van Der Burg, Tom H. M. Ottenhorf, Annemieke Geluk, Maria Johanna Philomena Schoenmaekers-Welters, Annemieke M. De Jong, Rienk Offringa, Rene Everardus Maria Toes